Roche authorized China enterprises to produce Tamiflu, which had a great public relations effect.
[Author: Internet repost from: Internet hits: 258; Updated: 2005- 12- 16]
Roche authorized Shanghai Pharmaceutical Group to take the lead in producing Tamiflu in the world, which not only gained market and profit, but also produced a huge public relations effect.
65438+February Local time 65438+February, Roche Holding AG issued a statement in Basel, Switzerland, announcing that it had authorized China Shanghai Pharmaceutical Group to produce Tamiflu (also known as "Tamiflu" and "Clofluclo") and that it had selected 12 potential regional partners to produce Tamiflu. As a result, Shanghai Pharmaceutical Group became the first foreign pharmaceutical company authorized to produce Tamiflu in the world.
According to the statement of Shanghai Pharmaceutical Group and Roche, Shanghai Pharmaceutical Group has been officially authorized to produce and sell oseltamivir raw materials and preparations in China except Hong Kong, Macao and Taiwan. The authorization agreement between the two companies stipulates that in the event of influenza epidemic, Shanghai Pharmaceutical Group can produce oseltamivir to meet government procurement. The trade name of oseltamivir is Tamiflu, but as Tamiflu is a special trade name registered by Roche in China, it will not be used in the future production of oseltamivir.
Public relations and market value are obvious.
65438+Feb 1 Gao Qiang, Minister of Health of China, said at a news conference in Beijing that he hoped to produce Tamiflu in China through technology transfer. Only half a month later, China enterprises were authorized to produce Tamiflu for the first time, which was related to the huge potential demand in China and Roche's concern for the whole pharmaceutical market in China.
165438+1In mid-October, the local Swiss Daily Herald reported that in view of the rapid development of the western medicine market in China, Swiss pharmaceutical giants have taken China as their development focus; In 2004, Roche invested 65.438+0.9 billion Swiss francs (US$ 654.38+0 is about 654.38+0.3 Swiss francs) in China. Starting from 2006, Roche's new pharmaceutical factory in Shanghai will be able to produce precious drugs worth 22 million Swiss francs every year; Roche Shanghai Research Center has applied for the first patent; Roche plans to increase the number of employees in China from 40 to 200 or 250 next year. The conclusion reached by Swiss pharmaceutical companies is that "China's pharmaceutical market will be a long-term developing country's market"-the world's first overseas Tamiflu production license is placed in a long-term developing market like China, and it is very concerned about the drug, and its public relations function can be imagined.
Tamiflu has an advantage in raw materials in China. Li Jie, our correspondent in Geneva, once called Roche to confirm that the raw materials for producing Tamiflu contained star anise. 165438+1October 9, Roche explained in detail that two-thirds of shikimic acid needed to make Tamiflu comes from Illicium verum. Only 30 kilograms of star anise can produce 1 kg shikimic acid, and every 6 grams of shikimic acid can produce 1 Tamiflu. Illicium verum is mainly produced in China and Viet Nam. China star anise is rich in raw materials and has a large export volume. This year, from 1 to 1, Guangdong Port exported octagonal 1649 tons, valued at 2.86 million US dollars. The supply of star anise is not a problem, but for Tamiflu, which is out of stock in many markets, getting raw materials nearby is conducive to speeding up production and occupying the market.
It is reported that Roche's licensing fee will be determined according to sales, and Shanghai Pharmaceutical Group said that its products will have a price advantage. It is estimated that 200,000 doses will be produced every month in the middle of next year-so there is no doubt that Roche will benefit from the production of Tamiflu in China.
Global pharmaceutical companies are anxiously waiting in line.
On June 5438+02, French Agence France-Presse reported the cooperation between Roche and Shanghai Pharmaceutical on the topic of "Roche and China reached a Tamiflu deal, while other partners were waiting in line". For some time, Roche has been criticized for its reluctance to disclose Tamiflu formula or authorize others to produce it. Roche's authorization has attracted the attention of global pharmaceutical companies.
Roche said that it has selected 12 partners from 200 applicants who are interested in producing Tamiflu. The company did not name these manufacturers, but said that these partners include major pharmaceutical manufacturers, large generic drug manufacturers and professional chemical manufacturers. These 12 companies have been invited to hold further in-depth consultations with Roche. William burns, CEO of Roche Pharmaceuticals, said: "We are not sure who can put into production quickly in the first half of 2006, but we can determine which partners can guarantee that there will be no shortage or help expand the geographical coverage." According to the news of US Senator Charles Schumer on February 8th, 65438, Roche is negotiating with Teva and Mylan. Roche allowed Schumer to announce similar news, in part because Schumer had been urging the company to approve generic drug companies to produce the drug.
"The company we have identified will further expand its production capacity, so that Roche's supply network can meet the future needs of governments around the world," said David Reddy, head of Roche's epidemic task force. Roche claims that the expanded production capacity can meet the orders of about 50 countries, regional governments and the World Health Organization. Roche will donate 3 million copies of Tamiflu to the World Health Organization as a reserve, which will be put into the epidemic center when the possible spread of the epidemic is quickly limited and slowed down. The production capacity will be gradually established from the middle of 2006, and priority will be given to meeting the needs of South Korea and Malaysia.
It is reported that Roche has agreed to freely produce its own version of Tamiflu in Thailand, the Philippines and Indonesia. These countries have no restrictions on drug patents, and will also provide basic ingredients for manufacturers in Vietnam and India for local packaging.
According to Article 39, paragraph 3, of the TRIPS Agreement, member states shall protect all data that meet the following five conditions:
The information is submitted in order to obtain the market license of the product in the member countries; The product for which market permission is sought is medicine.
Or agricultural chemical products; Products seeking market permission contain new chemical components; Before submitting the data,
Not disclosed; The research and development of data requires considerable efforts. Among them, about "new chemical constituents" and "no
The words such as "fair commercial use" are vague and do not directly mention exclusivity. Therefore, the country
There are also different understandings of this definition. For example, in the United States, Japan and most western European countries, people
It is generally believed that data protection and data monopoly are completely equivalent. Members of the Agreement on Trade-Related Aspects of Intellectual Property Rights are concerned about data protection.
The provisions of the protection period are also very different, ranging from 5 years to 15 years, and the protection period in most countries is 5 years. bag
Many countries, including China, Egypt, South Africa and Saudi Arabia, have formulated relevant laws and regulations, including
Many developing countries, including Argentina, Cuba, Indonesia, the Philippines and India, have not yet done so.
Make clear rules.
/c？ m = 9 f 65 CB 4 A8 c 8507 ed 4 fece 763 105392230 e 54 f 73260958 a 463 f 8 b 8448 e 435075 c 0223 a 6a 66 c 6940 1 9988 e 2c 7006 db 0d 07 BDB 52 172405 b 6 1 f 58 cc 9 fc 089 fac 9p = 877 EC 1 15d 9 c 54 AEC 0 be 29 162554 e & amp； User = Baidu
The change of market structure and the rise of emerging markets
Over the years, the world pharmaceutical market has been concentrated in the United States, Europe, Japan and other places, and these developed countries account for 80% of the global pharmaceutical market. However, in recent years, the market share of these countries has shown a downward trend. The emerging markets (Brazil, China, India, Indonesia, Mexico, Russia and Turkey) known as "E7 Group" have risen among global pharmaceutical enterprises with strong growth momentum, and their share in the global pharmaceutical market is expected to increase from 8% in 2006 to 65,438+065,438+0. It is predicted that in the growth of global pharmaceutical market, the contribution rate of seven major pharmaceutical markets, such as the United States, Japan and Germany, will be less than 50% for the first time in 2008, while the contribution rate of seven emerging markets will be close to 25% for the first time. In 2008, the total market size of "E7 Group" will increase by 12%~ 13%, reaching $85 billion to $90 billion, which contains huge business opportunities.
/c？ m = 9d 78d 5 13d 9d 437 AE 4 f 9e 97697d 12c 0 17 1343 f 1652 ba0d 3020 ea 3843 c 96732d 4250 1 7 E6 AC 26520772d 5d 20 a 14 16e 3948p = 856 f 89 16d 9 c 7 1 eff 57 ee 956d 584 b & amp； User = Baidu
Many developing countries, including Indonesia, the Philippines and India, have not made clear provisions on this. Data protection and drug patent data exclusivity are often related to drugs ... In the past, some people advocated that developing countries opposed the patent system, but with the rise of the domestic pharmaceutical industry and considering the concerns of foreign companies about intellectual property rights in India, the position of the Indian government is as follows. ...
Mint, as an authentic Chinese herbal medicine, has eight patents in the United States. A Japanese company also applied for patents of Danggui Shaoyao Decoction and Shaoyao Gancao Decoction in the United States, and clearly put forward that Paeonia lactiflora is the active ingredient. This means that if China's related proprietary Chinese medicines are exported to the United States, they are likely to be detained or charged a high patent fee in the name of infringing intellectual property rights.
According to the figures previously published by China National Intellectual Property Administration, Japanese and Korean have become absolute winners in the international market of Chinese herbal medicines, with varieties accounting for 80% ~ 90%, while China's preparations only account for 3% ~ 5% in the international market.
It is noteworthy that Indonesia and other countries have classified their traditional medicines as state secrets, and enterprises in other countries have no right to use them at will.
/c？ m = 9 f 65 CB 4 A8 c 8507 ed 4 fece 763 105392230 e 54 f 72 b 669 c 83482 e 87 c 85 f 93 130 a 1 1 87 ba 6 EC 79734 d5b 84d 80 f 2747 f 4 1802 bde 73 1065438p = 9a 769 a 42928408 ff 57 EC 9638594 e & amp； User = Baidu
China has established food safety cooperation mechanisms with the Philippines and Indonesia.
-
China Food Industry Network (09: 10 2007 10 30)
China has established food safety cooperation mechanisms with the Philippines and Indonesia.
10 10/28, AQSIQ signed meeting minutes with relevant parties in the Philippines and Indonesia respectively, and agreed to establish a food safety cooperation mechanism, timely notify and actively consult the quality and safety issues in bilateral food trade, and properly solve them. Li Changjiang, director of AQSIQ, attended the signing ceremony, and Wei Chuanzhong, deputy director, signed the memorandum on behalf of China.
It is understood that during the first China-ASEAN Ministerial Conference on Quality Supervision, Inspection and Quarantine held in Nanning, AQSIQ held bilateral consultations with food safety authorities of some ASEAN countries, and exchanged views on issues of common concern such as import and export food safety.
In the minutes of the meeting signed with the Philippine Ministry of Health, China and the Philippines reviewed the past cooperation in the field of food safety, especially the cooperation and latest progress in dealing with the students' discomfort in Cebu Province. The two sides agreed to continue to cooperate so that this incident can be solved fairly and properly.
According to the minutes of the meeting, China and the Philippines exchanged views on formaldehyde residues in food. China hopes that the Philippine side will treat the problem of formaldehyde residues in food scientifically. The Philippine side said that it is evaluating and studying this and will adjust relevant policies according to the evaluation results.
In the minutes of the meeting signed with the Indonesian Drug and Food Administration, the two sides pointed out that there were some problems in the cooperation, such as the lack of effective information exchange and sufficient technical cooperation. The two sides also exchanged views on the problem of formaldehyde residue in food and agreed that technical experts would carry out cooperative research on this issue.
In addition, AQSIQ also informed the Philippines and Indonesia of a series of measures recently taken by the China government to ensure food safety.
In terms of food safety cooperation mechanism, China and the Philippines, China and Indonesia all agreed to adopt this mechanism: first, timely notify and actively negotiate the quality and safety issues in bilateral food trade and properly solve them; The second is to establish channels for exchanges, communication and mutual visits between managers and technical experts of both sides; Third, timely exchange laws, regulations, standards, inspection procedures, methods and their latest changes related to the inspection and supervision of imported food. Fourth, timely inform the relevant information of import and export food, and cooperate with the crackdown on illegal import and export food.
/c？ m = 9d 78d 5 13d 9d 437 AE 4 f 9e 97697d 12c 0 17 1343 f 1652 ba0d 3020 ea 3843 c 96732d 4250 1 7 E6 AC 26520772d 5d 20 a 14 16e 3948p = ce 63 c 64 ad 3d D5 BF 004 BD 9 b 7d 0 c 08 & amp； User = Baidu
Indian minister of industry and commerce issued a statement on issues related to Doha negotiations.
2008-5-23
Indian Minister of Industry and Commerce Nath 16 issued a statement saying that major trading countries such as the United States and the European Union should show "leadership" in the current Doha negotiations, instead of shifting all the responsibility for the success of the negotiations to developing countries.
Nath said in his statement that whether the Doha negotiations can be concluded before the end of 2008 depends on many factors. The most important thing is whether the member countries that have enjoyed the greatest fruits of trade liberalization are willing to contribute to the realization of the goal of Doha negotiations-"development". If the Doha negotiations fail to fulfill the development promise and become another round of market access for rich countries, then the current efforts of developing countries, including India, will not succeed.
Regarding agriculture, Nath said that India's primary task is to ensure the livelihood of poor and disadvantaged farmers. Therefore, we must first solve the problems of special commodities and special safeguard measures. He criticized the United States and Keynes Group for asking developing countries to provide lists of special commodities on the grounds of transparency, but refused to provide their own lists of sensitive commodities, saying that the three standards of G33 on special commodities, namely livelihood security, rural development and food safety, could meet the requirements of transparency.
Regarding the negotiation of rules, Nath said in his statement that the proposals on anti-dumping and fishery subsidies have been severely criticized by many countries. The proposal on fishery subsidies will threaten the livelihood of millions of fishermen in India. In this regard, India, China and Indonesia have recently put forward new proposals, which should be seriously considered by all parties concerned. Regarding anti-dumping, he said that some people tried to please a country through the text, but the ruling of WTO Appellate Body in the "Zero" case showed that such efforts were untenable. He stressed that India and many developing countries will not support the conclusion of agricultural and non-agricultural negotiations without amending the anti-dumping and fishery subsidies texts.
Regarding services, the statement stated that market access for mode 1 and mode 4 is very important for the balance between India and some developing countries, while the current service trade negotiations focus on mode 3, which mainly involves the interests of developed countries.
/c？ m = 9 f 65 CB 4 A8 c 8507 ed 4 fece 763 105392230 e 54 f 7227492964868d 4 e 4 1 DCE 204 c 4 1 3037 BFA 6567 f 4 F5 b8 e 990 f 2747 f 4 1802 BD 866 134644587 ea 097p = 9c 6 189 16d 9 c 305 ff 57 eed 53d 7 f & amp； User = Baidu
Almost.